Expanding the study of ribociclib (LEE011) in advanced breast cancer
Novartis is recruiting men and premenopausal and postmenopausal women with hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer with no prior hormonal therapy for their advanced disease. By participating in this study, you may receive an investigational drug called ribociclib (LEE011) in combination with another drug called letrozole used to treat HR+, HER2- advanced breast cancer. All participants will receive care from a study team of health care professionals at a clinical study site.
As with all clinical trials, you have the right to leave the study at any time, for any reason.